Stargardt Disease clinical trials at UC Health
1 research study open to new patients

• Phase 2 Tolerability and Effects of ALK-001 on Stargardt Disease

  open to eligible people ages 12-60

  The purpose of this study is to determine the long term safety and tolerability of ALK-001 (C20-D3-retinyl acetate), and to explore the effects of ALK-001 on the progression of Stargardt disease in patients between the ages of 12 and 60 years old. Funding Source - FDA OOPD

  at UCLA

Last updated: January 2018